Breaking News

IMAB Licenses Phase II Ferring Compound

Olamkicept is under development to treat autoimmune disease

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ferring Pharmaceuticals and IMAB have signed a license agreement granting IMAB exclusive rights to olamkicept (pINN) in Asia. Olamkicept is a Phase II ready recombinant protein inhibitor of the interleukin-6 pathway, which is associated with inflammatory conditions such as inflammatory bowel diseases (IBD) and rheumatoid arthritis. IMAB will fund further product development in exchange for an exclusive license in Asia with an option for worldwide use, with the goal of realizing the potential...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters